• Bioptigen ophthalmic SD-OCT system earns CE Mark

    Medical device developer Bioptigen has received regulatory approval to market its handheld Envisu C2000-series ophthalmic spectral-domain optical coherence tomography (SD-OCT) systems for clinical use within the EU.
    Dec. 19, 2011

    Medical device developer Bioptigen (Research Triangle Park, NC) has received regulatory approval to market its handheld Envisu C2000-series ophthalmic spectral-domain optical coherence tomography (SD-OCT) systems for clinical use within the EU. The systems use low-power, near-infrared (IR) light to generate real-time, high-resolution, depth-resolved images of eye structures, enabling further understanding in disease progression, detection, and treatment.

    The Envisu C2000-series should prove especially useful for physicians treating non-ambulatory patients, as well as those suffering from conditions such as nystagmus, which causes involuntary eye movement, says Dr. Eric Buckland, Bioptigen's president and CEO.

    Availability of Envisu C-series handheld clinical ophthalmic imaging systems in the U.S. is dependent upon review and market clearance by the U.S. FDA.

    The National Institutes of Health recently awarded Bioptigen a grant to investigate a compact, handheld device for use with premature and neonatal infants.

    For more information, please visit www.bioptigen.com.

    -----

    Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

    Follow OptoIQ on your iPhone; download the free app here.

    Subscribe now to BioOptics World magazine; it's free!

    Sign up for Laser Focus World Newsletters
    Get the latest news and updates.

    Voice Your Opinion!

    To join the conversation, and become an exclusive member of Laser Focus World, create an account today!